You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum doublets

Showing 1 - 25 of 1,737
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Adenocarcinoma Trial in ZhengZhou (CIK, chemo)

Terminated
  • Lung Adenocarcinoma
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
May 10, 2021

Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)

Active, not recruiting
  • Small Cell Carcinoma
  • +3 more
  • Palo Alto, California
  • +9 more
May 12, 2022

Metastatic Gastro-esophageal Adenocarcinoma Trial in Regina, Saskatoon (FOLFOX and FOLFIRI)

Terminated
  • Metastatic Gastro-esophageal Adenocarcinoma
  • FOLFOX and FOLFIRI
  • Regina, Saskatchewan, Canada
  • +1 more
Oct 29, 2020

High Grade Neuroendocrine Tumors Trial in Saint Louis (Cabozantinib, Blood for plasma biomarkers, Tissue biopsy)

Recruiting
  • High Grade Neuroendocrine Neoplasms
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 11, 2021

Pancreatic Cancer Trial in Modena (LDR, Gem-based doublets, SBRT)

Recruiting
  • Pancreatic Cancer
  • LDR
  • +2 more
  • Modena, MO, Italy
    Azienda Ospedaliero-Universitaria Policlinico di Modena
Dec 8, 2022

Uterine Cervical Tumors, Chemoradiotherapy, Angiogenesis Trial in Wuhan (Hydrochloride anlotinib, cis Platinum/carboplatin,

Recruiting
  • Uterine Cervical Neoplasms
  • +2 more
  • Hydrochloride anlotinib
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
May 17, 2022

NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Jun 26, 2023

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
May 24, 2023

Small Cell Lung Carcinoma Trial in Worldwide (Pembrolizumab/Vibostolimab Co-Formulation, Saline , Etoposide)

Recruiting
  • Small Cell Lung Carcinoma
  • Pembrolizumab/Vibostolimab Co-Formulation
  • +5 more
  • Los Angeles, California
  • +122 more
Jan 27, 2023

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB Trial in Heidelberg (Atezolizumab)

Recruiting
  • NSCLC Stage II
  • +2 more
  • Heidelberg, BaWü, Germany
    Thoraxklinik Heidelberg gGmbH
Apr 25, 2021

Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • Nagoya, Aichi, Japan
  • +9 more
Jan 23, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

GSTP1 and Other Gene Polymorphisms With Platinum-induced

Not yet recruiting
  • Non-small Cell Lung Cancer
  • GSTP1 A313G （AA）
  • (no location specified)
Nov 16, 2023

NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
  • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
  • Tianjing, Tianjin, China
    Tianjin cancer hospital
Nov 3, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

Metastatic Non-squamous Non Small Cell Lung Cancer Trial in Worldwide (Cosibelimab, Cisplatin, Carboplatin)

Active, not recruiting
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Vitória, Brazil
  • +21 more
Aug 17, 2022

Extensive-stage Small-cell Lung Cancer Trial in Pittsburgh (Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection,

Not yet recruiting
  • Extensive-stage Small-cell Lung Cancer
  • Durvalumab 50 MG/1 ML Intravenous Solution
  • +4 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Oct 31, 2022

NSCLC (NSCLC) Trial (Ociperlimab, Placebo, Tislelizumab)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • (no location specified)
Mar 17, 2023

Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)

Terminated
  • Carcinoma, Small Cell Lung
  • RRx-001 + eLOOP Device
  • Cisplatin/carboplatin plus etoposide
  • Denver, Colorado
  • +17 more
Sep 30, 2022

Carcinoma, Small Cell Lung Trial in United States (RRx-001 + eLOOP Device, Cisplatin/carboplatin plus etoposide)

Active, not recruiting
  • Carcinoma, Small Cell Lung
  • RRx-001 + eLOOP Device
  • Cisplatin/carboplatin plus etoposide
  • Tampa, Florida
  • +5 more
Oct 3, 2022

Cancer of Unknown Primary Site Trial in Worldwide (Alectinib, Vismodegib, Ipatasertib)

Active, not recruiting
  • Cancer of Unknown Primary Site
  • Blacktown, New South Wales, Australia
  • +140 more
Jan 6, 2023

Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)

Not yet recruiting
  • Cancer
  • +3 more
  • Patients suffering from chemotherapy-induced ototoxicity
  • (no location specified)
Jun 29, 2023